Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the efficacy and safety of orally administered
DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).
Oral DS107/Placebo capsules will be administered for 16 weeks. The study will enrol
approximately 200 subjects.